Company Description
Acesis Holdings Corporation together with its wholly-owned subsidiaries, is an emerging, pre-phase 1 (first-in-man “FIM”) clinical, biotechnology company focused on men’s health.
Since the incorporation of ABI in the State of Colorado on March 11, 2015, we have been developing novel treatments for low testosterone levels in males (“Low–T”).
The Company’s point of differentiation, compared to its competitors, is that its drug pipeline (peptides) is not a steroid or a hormone, but is intended to induce the body (specifically, the testes, which is the major natural site of T synthesis in men) to produce its own testosterone.
The Company’s lead peptide, ACE-167, has been designed to act through a novel molecular mechanism to induce the Leydig cells of the testis to synthesize testosterone thereby restoring endogenous T production.
The unique attributes of ACE-167, including its novel mechanism of action and non-steroidal composition, and its ability to induce endogenous levels of T production will need to be proven by the completion of clinical trials and regulatory review.
It is our goal to prove that product candidate ACE-167 does not confer the adverse effects in the body as reported for the marketed T formulations.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Konstantinos Karatzas |
Contact Details
Address: 9233 Park Meadows Dr., Ste. 108 Lone Tree, CO 80124 United States | |
| Phone | (720) 389-0650 |
| Website | acesisbio.com |
Stock Details
| Ticker Symbol | ACSB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001955728 |
| Employer ID | 88-4251528 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Konstantinos Karatzas | Chief Executive Officer, Director |
| Dr. Vassilios Papadopoulos | Director |
| Duane Charles Knight, Jr | Chief Financial Officer and Treasurer |
| Thomas B. Olson | Chief Operating Officer and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 15, 2023 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 30, 2023 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jun 9, 2023 | D/A | Filing |
| May 12, 2023 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Apr 7, 2023 | D/A | Filing |
| Mar 1, 2023 | D/A | Filing |
| Feb 10, 2023 | DRS | [Cover] Draft Registration Statement |
| Jan 11, 2023 | D | Notice of Exempt Offering of Securities |